From October 28 to 30, 2025, CPHI Worldwide, a grand event in the global pharmaceutical industry, was successfully held at the Messe Frankfurt in Germany. This year's exhibition brought together over 2,400 exhibitors from 166 countries and more than 62,000 professional visitors to discuss the latest development trends in the pharmaceutical industry.

Xieli team attended the exhibition with its specialty APIs, including Ursodeoxycholic acid, Diosmin, Hesperidin, and Troxerutin. Relying on strict quality control, stable supply capacity, and professional technical support, the company attracted great attention from numerous pharmaceutical enterprises around the world, who conducted in-depth discussions with the team. The communication at the booth was lively, and remarkable achievements were made in cooperation negotiations.

Ursodeoxycholic Acid: Facing the complex and ever-changing market environment, Xieli team actively communicated with potential and existing customers from Asia, Europe, and other regions. They conducted in-depth discussions on customized needs (such as special specifications and process consultation) and strategies to address market challenges, demonstrating the company's determination in technological research (e.g., impurity control) and quality improvement.

Diosmin and Hesperidin: As an important supplier in this field, Xieli had productive exchanges with a number of well-known pharmaceutical companies from Europe, Asia, South America, and other regions. Customers expressed interest in Xieli’s stable supply capacity and strategies for responding to price fluctuations of upstream raw materials. Both parties discussed deepening cooperation and ensuring long-term stable supply. The team also had detailed communications regarding the quality details feedback from customers.

Other Leading Varieties: Products such as Troxerutin and Berberine have continued to gain the trust of customers in traditional markets like South Korea and Russia due to their quality advantages. Cytisine has also attracted inquiries and cooperation intentions from European and domestic customers because of its potential in specific therapeutic fields. In addition, the company's layout in health product raw materials (such as Curcumin and Quercetin) and certain specialty APIs (such as Anastrozole) has also attracted market attention.

To maximize the value of participating in the exhibition, the team of Xieli formulated the goal of "consolidating regular customers, expanding new markets, and solidifying long-term cooperation" before the exhibition. Every negotiation and communication during the exhibition was carried out precisely around this goal, and substantial progress was finally achieved:

Consolidating Existing Cooperation: Conducted in-depth exchanges with strategic partners on supply chain optimization and directions for technological research.

Expanding Emerging Markets: Accurately connected with potential customers in the European market and demonstrated the ability to provide customized solutions.

Laying the Foundation for Long-Term Development: Promoted qualification certification, arranged on-site visits by customers, and solidified the foundation for cooperation.

In fact, this is not the first time that Xieli has participated in the CPHI series of exhibitions. By long-term dedication to the global market, the company has successfully promoted its products to regions and countries such as Asia, Europe, South America, and Southeast Asia through exhibitions like CPHI Frankfurt and CPHI China, establishing a high-quality brand image in the international market.

The conclusion of the exhibition is not an end, but a new starting point for global cooperation. In the future, Xieli will continue to optimize its global market layout, strengthen technological innovation and quality management. On the basis of its existing product lines, the company will accelerate the R&D and production of APIs, and continuously enhance its market competitiveness. It will continue to adopt an open and cooperative attitude, work hand in hand with global partners, and contribute to the progress and development of the global medical and health industry.